- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | Elicera Therapeutics AB: Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu | 171 | GlobeNewswire (Europe) | Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.03. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate | 146 | GlobeNewswire (Europe) | Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 10.03. | Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden) | 1 | Cision News | ||
| 06.03. | Elicera Therapeutics AB: Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients | 182 | GlobeNewswire (Europe) | Gothenburg, March 6, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.02. | Elicera Therapeutics AB: Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway | 1.000 | GlobeNewswire (Europe) | Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, today... ► Artikel lesen | |
| 18.02. | Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference | 4 | Cision News | ||
| 13.02. | Elicera Therapeutics AB Q4 Loss Widens | 1 | RTTNews | ||
| 13.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025 | 152 | GlobeNewswire (Europe) | Fourth quarter (October-December 2025)
Operating loss amounted to o SEK -7,129,626 (-2,911,958).
Loss for the period amounted to SEK -6,965,286 (-2,603,242).
Cash flow from operating activities... ► Artikel lesen | |
| 11.02. | Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study | 1 | Cision News | ||
| 22.01. | Elicera Therapeutics' CSO invited to present at multiple scientific conferences | 1 | Cision News | ||
| 09.01. | Elicera Therapeutics AB: Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors | 173 | GlobeNewswire (Europe) | Gothenburg, January 9, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 23.12.25 | Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 1 | Cision News | ||
| 14.11.25 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025 | 150 | GlobeNewswire (Europe) | Third quarter (July-September 2025)
Operating loss amounted to SEK 146,689 (-2,697,267).
Loss for the period amounted to SEK 304,153 (-2,514,629).
Cash flow from operating activities totaled SEK... ► Artikel lesen | |
| 13.11.25 | Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research | 1 | Cision News | ||
| 23.10.25 | Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 2 | Cision News | ||
| 19.09.25 | Elicera Therapeutics AB: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 228 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 29.08.25 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 251 | GlobeNewswire (Europe) | Second quarter (April-June 2025)
Operating loss amounted to SEK -2,892,341 (-5,841,409).
Loss for the period amounted to SEK -2,732,070 (-5,622,779).
Cash flow from operating activities totaled... ► Artikel lesen | |
| 25.08.25 | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 195 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 25.08.25 | Elicera Therapeutics AB: Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 | 222 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 28.05.25 | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 249 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,640 | +1,26 % | Evotec: Aktie profitiert von Kaufempfehlung | Die Aktie von Evotec legt heute um mehr als sechs Prozent zu. Die Privatbank Berenberg sieht in der konsequenten Integration von Künstlicher Intelligenz einen entscheidenden Wachstumstreiber bei Evotec... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 630,90 | -1,10 % | Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU | DJ Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU
Von Colin Kellaher
DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent... ► Artikel lesen | |
| BRAIN BIOTECH | 2,510 | +1,62 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,154 | -9,98 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.04.2026 / 15:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CSL | 84,06 | -0,26 % | CSL LIMITED: Notification of cessation of securities - CSL | ||
| BURCON NUTRASCIENCE | 1,320 | -2,22 % | Burcon NutraScience Corporation: Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| MANNKIND | 2,440 | +1,29 % | Leerink reiterates Outperform on MannKind stock, sees overreaction | ||
| OCULAR THERAPEUTIX | 8,200 | -1,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,455 | -0,07 % | Oxford Nanopore Tech - Director/PDMR Shareholding - LTIP and DBP awards | ||
| ADAPTIMMUNE THERAPEUTICS | 0,013 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 2,238 | +1,45 % | CODEXIS, INC. - 8-K, Current Report | ||
| CORMEDIX | 6,396 | +1,78 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen | |
| TELO GENOMICS | 0,026 | 0,00 % | Telo Genomics Corp.: Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma | Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 5,820 | +2,11 % | Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection | Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,469 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.